Skip to main content

Table 4 Concomitant, rescue, and anti-inflammatory medication (N = 51)

From: Randomized, double-blind, placebo-controlled study to evaluate the effect of treatment with an SPMs-enriched oil on chronic pain and inflammation, functionality, and quality of life in patients with symptomatic knee osteoarthritis: GAUDI study

Medication

Values

P-value

SPMs (N = 23)

Placebo (N = 28)

Concomitant medication at baseline, n (%)

 At baseline

10 (43.48)

7 (25.00)

0.164 (1)

 At week 4

2 (8.70)

2 (7.14)

0.383 (2)

 At week 8

2 (8.70)

2 (7.14)

0.383 (2)

 At week 12

3 (13.04)

4 (14.29)

0.313 (2)

Rescue medication, n (%)

 At week 4

0 (0.00)

0 (0.00)

 

 At week 8

0 (0.00)

0 (0.00)

 

 At week 12

0 (0.00)

0 (0.00)

 

Anti-inflammatory medication, n (%)

 At week 24

4 (17.39)

4 (14.29)

0.285 (2)

  1. (1) Chi-Square test; (2) Fisher's test. SPMs: specialized pro-resolving lipid mediators